Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions

Completed · Not applicable

Conditions studied: Coronary Artery Disease

In brief

This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects will be treated with the orbital atherectomy system and adjunctive stent. All subjects will be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call or clinical follow up at each anniversary until study is closed.

Key facts

Study ID: NCT01092416
Run by: Abbott Medical Devices
People needed: 443
Starts: 2010-05-01
Expected to finish: 2016-01-01
Last updated by the study team: 2023-07-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subjects must be 18 or older.
Subjects must have a clinical indication for coronary intervention.
CK and CK-MB must be less than or equal to the upper limit of lab normal value within 8 hours prior to the procedure.
The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure.
The target vessel must be a native coronary artery with a stenosis of >= 70% and < 100%.
The target vessel reference diameter must be >= 2.5mm and <= 4.0 mm.
The lesion length must not exceed 40 mm.
The target vessel must have a TIMI flow 3 at baseline.
The target lesion must have evidence of severe calcium deposit at the lesion site based on the protocol criterion.
The lesion must be crossable with the study guide wire.

You may not qualify if…

Inability to understand the study or a history of non-compliance with medical advice.
Unwilling or unable to sign the ORBIT II Informed Consent Form (ICF).
History of any cognitive or mental health status that would interfere with study participation.
Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.).
Female subjects who are pregnant or planning to become pregnant within the study period.
Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications.
Known sensitivity to contrast media, which cannot be adequately pre-medicated.
Diagnosed with chronic renal failure or has a serum creatinine level >2.5 mg/dl.
Experienced acute MI (STEMI or non-STEMI: CK and CK-MB greater than 1 times the upper limit of lab normal) within 30 days prior to index procedure.
History of major cardiovascular intervention within 30 days.
Evidence of current (within 6 months) left ventricular ejection fraction ≤ 25%.
NYHA class III or IV heart failure.
History of a stroke or transient ischemic attack (TIA) within 6 months.
Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months.
History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.
Concurrent medical condition with a life expectancy of less than 12 months.
History of immune deficiency.
Uncontrolled insulin dependent diabetes.
Evidence of active infections on the day of the index procedure.
Subject has planned cardiovascular intervention within 60-days post index procedure.
Subject is not an acceptable candidate for emergent coronary artery bypass surgery.
Subject with known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide.
Subject with 3 lesions requiring intervention.
Subject with 2 lesions unless the treatment of the lesions is staged. The non target lesion must first be treated at least 12 hours prior to the index procedure. The subject's CK and CK-MB must be less than or equal to one times the upper limit of the lab normal value 12 ± 2 hours post procedure and there were no procedural complications during the first lesion intervention.
Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass.

Where it is running

Baptist Montgomery South — Montgomery, Alabama, United States
Mercy Gilbert — Gilbert, Arizona, United States
Cedar Sinai Los Angeles — Beverly Hills, California, United States
Good Samaritan Hospital — Los Angeles, California, United States
Eisenhower Medical Center — Palm Springs, California, United States
Desert Cardiology Center — Rancho Mirage, California, United States
Sutter Memorial Hospital — Sacramento, California, United States
Florida Hospital Memorial — Daytona Beach, Florida, United States
North Florida Regional — Gainesville, Florida, United States
Munroe Regional Medical Center — Ocala, Florida, United States
Florida Hospital — Orlando, Florida, United States
Orlando Regional — Orlando, Florida, United States
Palm Beach Gardens — Palm Beach Gardens, Florida, United States
Winter Haven — Winter Haven, Florida, United States
Emory University — Atlanta, Georgia, United States
Indiana Heart Hospital — Indianapolis, Indiana, United States
Saint Vincents Indianapolis — Indianapolis, Indiana, United States
Community Hospital — Munster, Indiana, United States
Iowa Heart — Des Moines, Iowa, United States
Kansas University Medical Center — Kansas City, Kansas, United States
King's Daughters / Kentucky Heart Foundation — Ashland, Kentucky, United States
Ochsner Clinic Foundation — New Orleans, Louisiana, United States
Maine Medical Center — Portland, Maine, United States
Cape Cod Research Institute — Hyannis, Massachusetts, United States
Trinity Hospital — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.